Abstract
We recently reported that apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor growth and improve survival in a mouse model of ovarian cancer. The current study was designed to examine whether inhibition of angiogenesis is one of the mechanisms for the observed anti-tumorigenic effects. The apoA-I mimetic peptide L-5F had no affect on proliferation and cell viability of human umbilical vascular endothelial cells (HUVECs) in the basal state; however, treatment with L-5F at 1, 3, and 10 μg ml(-1), dose-dependently inhibited both vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced proliferation, cell viability, migration, invasion and tube formation in HUVECs. L-5F inhibited VEGF- and bFGF-induced activation of their corresponding receptors, VEGFR2 and FGFR1, as well as downstream signaling pathways, including Akt and ERK1/2. MicroCT scanning and immunohistochemistry staining demonstrated that daily injection of L-5F (10 mg kg(-1)) decreased both the quantity and size of tumor vessels in mice. L-5F treated mice showed significantly reduced levels of VEGF in both tumor tissue and the circulation, which is consistent with in vitro data showing that L-5F inhibited production and secretion of VEGF from mouse and human ovarian cell lines in the absence and presence of exogenously added lysophosphatidic acid, a potent tumor promoter. In conclusion, our data that L-5F inhibits angiogenesis suggests that apoA-I mimetic peptides may serve as novel anti-angiogenesis agents for the treatment of angiogenesis-associated diseases, including cancer.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Amino Acid Sequence
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Apolipoprotein A-I / chemistry*
-
Blood Vessels / drug effects
-
Blood Vessels / pathology
-
Cell Line, Tumor
-
Cell Movement / drug effects
-
Cell Proliferation / drug effects
-
Cell Survival / drug effects
-
Cells, Cultured
-
Endothelial Cells / cytology
-
Endothelial Cells / drug effects
-
Endothelial Cells / metabolism
-
Extracellular Signal-Regulated MAP Kinases / metabolism
-
Female
-
Fibroblast Growth Factor 2 / pharmacology*
-
Gene Expression / drug effects
-
Gene Expression / genetics
-
Humans
-
Intercellular Signaling Peptides and Proteins
-
Lysophospholipids / pharmacology
-
Mice
-
Mice, Inbred C57BL
-
Models, Biological
-
Molecular Mimicry
-
Molecular Sequence Data
-
Neovascularization, Pathologic / drug therapy*
-
Neovascularization, Pathologic / pathology
-
Neovascularization, Physiologic / drug effects
-
Ovarian Neoplasms / blood supply*
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / metabolism
-
Ovarian Neoplasms / pathology
-
Peptide Fragments / pharmacology
-
Peptide Fragments / therapeutic use*
-
Peptides / pharmacology
-
Peptides / therapeutic use*
-
Phosphorylation / drug effects
-
Proto-Oncogene Proteins c-akt / metabolism
-
Receptor, Fibroblast Growth Factor, Type 1 / metabolism
-
Signal Transduction / drug effects*
-
Vascular Endothelial Growth Factor A / genetics
-
Vascular Endothelial Growth Factor A / metabolism
-
Vascular Endothelial Growth Factor A / pharmacology*
-
Vascular Endothelial Growth Factor Receptor-2 / metabolism
Substances
-
Angiogenesis Inhibitors
-
Apolipoprotein A-I
-
Intercellular Signaling Peptides and Proteins
-
L-4F peptide
-
Lysophospholipids
-
Peptide Fragments
-
Peptides
-
Vascular Endothelial Growth Factor A
-
peptide 5F
-
Fibroblast Growth Factor 2
-
Fgfr1 protein, mouse
-
Receptor, Fibroblast Growth Factor, Type 1
-
Vascular Endothelial Growth Factor Receptor-2
-
Proto-Oncogene Proteins c-akt
-
Extracellular Signal-Regulated MAP Kinases
-
lysophosphatidic acid